Article ; Online: Hydroxychloroquine and Azithromycin Combination in the Management of COVID-19 Infection: Safety and Effectiveness Challenges.
2021 Volume 17, Issue 2, Page(s) 143–151
Abstract: Background: The treatment of COVID-19 disease remains a dilemma so far because there is no approved therapy for it. This study aimed to evaluate the use of hydroxychloroquine and azithromycin combination in treatment.: Objectives: This study was ... ...
| Abstract | Background: The treatment of COVID-19 disease remains a dilemma so far because there is no approved therapy for it. This study aimed to evaluate the use of hydroxychloroquine and azithromycin combination in treatment. Objectives: This study was carried out to determine the safety and effectiveness of hydroxychloroquine and azithromycin combination in COVID 19 patients. Methods: This study included 90 adult COVID 19 patients. Treatment of all patients followed Egyptian Ministry of Health COVID-19 protocols, receiving a combination of hydroxychloroquine 400mg twice on day 1, then 200 mg twice daily in addition to azithromycin 500mg/day for 5 days. ECG findings, especially the QTc interval, were assessed before and after 5 days from the administration. Results: All patients showed a statistically significant higher post-treatment QTc readings (433.6 ± 37.2) compared to baseline QTc (402.4 ± 31.3) at p<0.005 with a median QTc prolongation by 26 mSec and IQR (17.8-41.3), but without serious clinical complications. Only 5.6% of patients showed QTc more than 500 mSec and no torsade de points or cardiac arrest. Geriatric patients were at higher risk for QTc prolongation compared to patients aged less than 65 years but without a significant difference as regards the median max QTc difference p˂0.65. The expected therapeutic effectiveness was 82.5% for moderate patients compared to 26% for severe patients (P<0.005). Conclusion: In a modest safety profile, we support the evidence that HQ/AZ therapy can be used to treat Covid-19 infection with more effectiveness in moderate rather than severe cases, which might be a reflection of the time of administration in the disease course. |
|||||
|---|---|---|---|---|---|---|
| MeSH term(s) | Adult ; Aged ; Azithromycin/adverse effects ; COVID-19/drug therapy ; Electrocardiography ; Humans ; Hydroxychloroquine/adverse effects ; Long QT Syndrome/chemically induced ; Long QT Syndrome/epidemiology ; SARS-CoV-2 | |||||
| Chemical Substances | Hydroxychloroquine (4QWG6N8QKH) ; Azithromycin (83905-01-5) | |||||
| Language | English | |||||
| Publishing date | 2021-07-27 | |||||
| Publishing country | United Arab Emirates | |||||
| Document type | Journal Article | |||||
| ZDB-ID | 2250840-5 | |||||
| ISSN | 2212-3911 ; 1574-8863 | |||||
| ISSN (online) | 2212-3911 | |||||
| ISSN | 1574-8863 | |||||
| DOI | 10.2174/1574886316666210727152609 | |||||
| Shelf mark |
|
|||||
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 6400: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.